

DARWIN EU® - Cancer incidence during pregnancy

First published: 14/07/2026

Last updated: 14/07/2026

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000001059

Study ID

1000001059

DARWIN EU® study

Yes

Study countries

 Norway

 Spain

 United Kingdom

Study description

Few studies have examined the incidence of cancer during pregnancy, and existing evidence from studies conducted in Europe is limited. Real-World Evidence (RWE) regarding the precise incidence of cancer during pregnancy can help address this gap by providing more recent estimates from different European countries, informing future research priorities, and contributing to evidence-based decision-making in this vulnerable population.

Study status

Ongoing

Research institutions and networks

Institutions

Department of Medical Informatics - Health Data Science, Erasmus Medical Center (ErasmusMC)

 Netherlands

First published: 03/11/2022

Last updated: 02/05/2024

Institution

Educational Institution

ENCePP partner

Networks

Data Analysis and Real World Interrogation Network (DARWIN EU®)

 Belgium

-  Croatia
-  Denmark
-  Estonia
-  Finland
-  France
-  Germany
-  Greece
-  Hungary
-  Italy
-  Netherlands
-  Norway
-  Portugal
-  Spain
-  Sweden
-  United Kingdom

First published: 01/02/2024

Last updated: 30/04/2025

Network

Contact details

Study institution contact

Natasha Yefimenko study@darwin-eu.org

Study contact

study@darwin-eu.org

Primary lead investigator

Berta Raventos

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 12/06/2026

Actual: 12/06/2026

Study start date

Planned: 07/07/2026

Actual: 07/07/2026

Date of final study report

Planned: 16/10/2026

Sources of funding

- EMA

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Data collection methods:

Secondary use of data

Study design:

A cohort study will be conducted using routinely collected health data from 3 data sources from 3 countries across Europe and in 1 European Union (EU) member state.

Main study objective:

- A disease epidemiology study to address objective 1, assessing incidence of cancer occurring during pregnancy;
- A characterisation study to address objective 2, describing new primary cancers diagnosed during pregnancy.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Cancer cells present

Population studied

Short description of the study population

All recorded pregnancy episodes of females aged 12 to 55 years at pregnancy start (i.e. index date) will be considered for inclusion.

Age groups

- **Adult and elderly population (≥ 18 years)**
 - Adults (18 to < 65 years)
 - Adults (18 to < 46 years)
-

Special population of interest

Pregnant women

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Norwegian Linked Health registry at University of Oslo, Pregnancy cohort
The Information System for Research in Primary Care (SIDIAP)
Clinical Practice Research Datalink (CPRD) GOLD

Use of a Common Data Model (CDM)

CDM mapping

Yes

CDM Mappings**CDM name**

OMOP

CDM website

<https://www.ohdsi.org/Data-standardization/>

CDM version

<https://ohdsi.github.io/CommonDataModel/cdm54.html>

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No